{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:13Z","timestamp":1787170753227,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hypoxic-ischemic encephalopathy (HIE) is a major cause of acute neonatal brain injury and can lead to disabling long-term neurological complications. Treatment for HIE is limited to supportive care and hypothermia within 6 h injury which is reserved for full-term infants. Preclinical studies suggest the potential for cell-based therapies as effective treatments for HIE. Some clinical trials using umbilical cord blood cells, placenta-derived stem cells, mesenchymal stem cells (MSCs), and others have yielded promising results though more studies are needed to optimize protocols and multi-center trials are needed to prove safety and efficacy. To date, the therapeutic effects of most cell-based therapies are hypothesized to stem from the bystander effect of donor cells. Transplantation of stem cells attenuate the aberrant inflammation cascade following HIE and provide a more ideal environment for endogenous neurogenesis and repair. Recently, a subset of MSCs, the multilineage-differentiating stress-enduring (Muse) cells have shown to treat HIE and other models of neurologic diseases by replacing dead or ischemic cells and have reached clinical trials. In this review, we examine the different cell sources used in clinical trials and evaluate the underlying mechanism behind their therapeutic effects. Three databases\u2013PubMed, Web of Science, and ClinicalTrials.gov\u2013were used to review preclinical and clinical experimental treatments for HIE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/bc.bc_7_21","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T08:21:48Z","timestamp":1617092508000},"page":"13-17","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Cell-based treatment for perinatal hypoxic-ischemic encephalopathy"],"prefix":"10.4103","volume":"7","author":[{"given":"You Jeong","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesario V.","family":"Borlongan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Dezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240830","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.earlhumdev.2010.05.010","article-title":"Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy","volume":"86","author":"Kurinczuk","year":"2010","journal-title":"Early Hum Dev"},{"key":"R2-4-20240830","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ana.23647","article-title":"Neonatal encephalopathy: An inadequate term for hypoxic-ischemic encephalopathy","volume":"72","author":"Volpe","year":"2012","journal-title":"Ann Neurol"},{"key":"R3-4-20240830","first-page":"609813","article-title":"Perinatal hypoxic-ischemic encephalopathy","volume":"2011","author":"Lai","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"R4-4-20240830","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1824-7288-35-14","article-title":"Perinatal hypoxic-ischemic encephalopathy: Epileptic and paretic outcome at one year of age","volume":"35","author":"Allemand","year":"2009","journal-title":"Ital J Pediatr"},{"key":"R5-4-20240830","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.nainr.2011.07.004","article-title":"Hypoxic ischemic encephalopathy: Pathophysiology and experimental treatments","volume":"11","author":"Allen","year":"2011","journal-title":"Newborn Infant Nurs Rev"},{"key":"R6-4-20240830","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/aps.2013.89","article-title":"Inflammatory responses in hypoxic ischemic encephalopathy","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R7-4-20240830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.22670","article-title":"Cell therapy for neonatal hypoxia-ischemia and cerebral palsy","volume":"71","author":"Bennet","year":"2012","journal-title":"Ann Neurol"},{"key":"R8-4-20240830","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pneurobio.2017.10.006","article-title":"Brain-immune interactions in perinatal hypoxic-ischemic brain injury","volume":"159","author":"Li","year":"2017","journal-title":"Prog Neurobiol"},{"key":"R9-4-20240830","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11940-007-0043-0","article-title":"Treatment of hypoxic-ischemic encephalopathy in newborns","volume":"9","author":"Glass","year":"2007","journal-title":"Curr Treat Options Neurol"},{"key":"R10-4-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2004.06.014","article-title":"Moderate hypothermia in neonatal encephalopathy: Efficacy outcomes","volume":"32","author":"Eicher","year":"2005","journal-title":"Pediatr Neurol"},{"key":"R11-4-20240830","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0140-6736(05)17946-X","article-title":"Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised trial","volume":"365","author":"Gluckman","year":"2005","journal-title":"Lancet"},{"key":"R12-4-20240830","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMcps050929","article-title":"Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy","volume":"353","author":"Shankaran","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-4-20240830","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0271678X15607881","article-title":"The effects of therapeutic hypothermia on cerebral metabolism in neonates with hypoxic-ischemic encephalopathy: An in vivo 1H-MR spectroscopy study","volume":"36","author":"Wisnowski","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"R14-4-20240830","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1933719108317299","article-title":"Reduction of brain injury in neonatal hypoxic-ischemic rats by intracerebroventricular injection of neural stem\/progenitor cells together with chondroitinase ABC","volume":"15","author":"Sato","year":"2008","journal-title":"Reprod Sci"},{"key":"R15-4-20240830","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/157488809789057419","article-title":"Chondroitin sulfate, a major niche substance of neural stem cells, and cell transplantation therapy of neurodegeneration combined with niche modification","volume":"4","author":"Sato","year":"2009","journal-title":"Curr Stem Cell Res Ther"},{"key":"R16-4-20240830","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000368396","article-title":"Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats","volume":"37","author":"Hattori","year":"2015","journal-title":"Dev Neurosci"},{"key":"R17-4-20240830","doi-asserted-by":"crossref","first-page":"44111","DOI":"10.1038\/srep44111","article-title":"Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats","volume":"7","author":"Nakanishi","year":"2017","journal-title":"Sci Rep"},{"key":"R18-4-20240830","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fneur.2018.00757","article-title":"Intravenous administration of bone marrow-derived mesenchymal stem cell, but not adipose tissue-derived stem cell, ameliorated the neonatal hypoxic-ischemic brain injury by changing cerebral inflammatory state in rat","volume":"9","author":"Sugiyama","year":"2018","journal-title":"Front Neurol"},{"key":"R19-4-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","article-title":"Stem cell therapies in clinical trials: Progress and challenges","volume":"17","author":"Trounson","year":"2015","journal-title":"Cell Stem Cell"},{"key":"R20-4-20240830","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1073\/pnas.0911647107","article-title":"Unique multipotent cells in adult human mesenchymal cell populations","volume":"107","author":"Kuroda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-4-20240830","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-4-431-56847-6_2","article-title":"Basic characteristics of muse cells","volume":"1103","author":"Wakao","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R22-4-20240830","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/0963689719844260","article-title":"Quantitative analysis of ssea3+cells from human umbilical cord after magnetic sorting","volume":"28","author":"Leng","year":"2019","journal-title":"Cell Transplant"},{"key":"R23-4-20240830","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-4-431-56847-6_8","article-title":"Acute myocardial infarction, cardioprotection, and muse cells","volume":"1103","author":"Minatoguchi","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R24-4-20240830","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-4-431-56847-6_9","article-title":"Application of muse cell therapy to stroke","volume":"1103","author":"Niizuma","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R25-4-20240830","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-4-431-56847-6_11","article-title":"Application of muse cell therapy for kidney diseases","volume":"1103","author":"Uchida","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R26-4-20240830","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-4-431-56847-6_13","article-title":"Current cell-based therapies in the chronic liver diseases","volume":"1103","author":"Nishina","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R27-4-20240830","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1253\/circj.CJ-20-0307","article-title":"Safety and efficacy of human muse cell-based product for acute myocardial infarction in a first-in-human trial","volume":"84","author":"Noda","year":"2020","journal-title":"Circ J"},{"key":"R29-4-20240830","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PCC.0000000000000324","article-title":"Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children","volume":"16","author":"Liao","year":"2015","journal-title":"Pediatr Crit Care Med"},{"key":"R30-4-20240830","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jcyt.2013.06.001","article-title":"Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: A preliminary clinical study","volume":"15","author":"Wang","year":"2013","journal-title":"Cytotherapy"},{"key":"R31-4-20240830","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/STROKEAHA.119.026589","article-title":"Intravenously transplanted human multilineage-differentiating stress-enduring cells afford brain repair in a mouse lacunar stroke model","volume":"51","author":"Abe","year":"2020","journal-title":"Stroke"},{"key":"R32-4-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pin.12129","article-title":"Muse cells, newly found non-tumorigenic pluripotent stem cells, reside in human mesenchymal tissues","volume":"64","author":"Wakao","year":"2014","journal-title":"Pathol Int"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_7_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:49Z","timestamp":1786649989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_7_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_7_21","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}